-
1
-
-
34447530283
-
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial
-
Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007; 370(9583): 230-239.
-
(2007)
Lancet
, vol.370
, Issue.9583
, pp. 230-239
-
-
Catovsky, D.1
Richards, S.2
Matutes, E.3
-
2
-
-
31544434508
-
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
-
Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107(3): 885-891.
-
(2006)
Blood
, vol.107
, Issue.3
, pp. 885-891
-
-
Eichhorst, B.F.1
Busch, R.2
Hopfinger, G.3
-
3
-
-
33947541773
-
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997
-
Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007; 25(7): 793-798.
-
(2007)
J Clin Oncol
, vol.25
, Issue.7
, pp. 793-798
-
-
Flinn, I.W.1
Neuberg, D.S.2
Grever, M.R.3
-
4
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2005.12.051
-
Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23(18): 4079-4088. (Pubitemid 46211313)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
Lerner, S.4
Plunkett, W.5
Giles, F.6
Andreeff, M.7
Cortes, J.8
Faderl, S.9
Thomas, D.10
Koller, C.11
Wierda, W.12
Detry, M.A.13
Lynn, A.14
Kantarjian, H.15
-
5
-
-
51649093353
-
Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia
-
Tam CS, O'Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112(4): 975-980.
-
(2008)
Blood
, vol.112
, Issue.4
, pp. 975-980
-
-
Tam, C.S.1
O'brien, S.2
Wierda, W.3
-
6
-
-
30744448409
-
A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
-
Wierda W, O'Brien S, Faderl S et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006; 106(2): 337-345.
-
(2006)
Cancer
, vol.106
, Issue.2
, pp. 337-345
-
-
Wierda, W.1
O'brien, S.2
Faderl, S.3
-
7
-
-
61849091076
-
Immunochemotherapy with Fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)
-
Abstract 325
-
Hallek M, Fingerle-Rowson G, Fink AM et al. Immunochemotherapy with Fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 325.
-
(2008)
Blood (ASH Annual Meeting Abstracts)
, vol.112
-
-
Hallek, M.1
Fingerle-Rowson, G.2
Fink, A.M.3
-
8
-
-
65749114275
-
Rituximab fludarabine and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: Final results from the International randomized phase III REACH trial
-
Abstract 1
-
Robak T, Moiseev SI, Dmoszynska A et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: Final results from the International randomized phase III REACH trial. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1.
-
(2008)
Blood (ASH Annual Meeting Abstracts)
, vol.112
-
-
Robak, T.1
Moiseev, S.I.2
Dmoszynska, A.3
-
9
-
-
37049022152
-
Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: Potential cure for an incurable disease
-
DOI 10.1517/14712598.7.12.1789
-
Boyiadzis M, Foon KA, Pavletic S. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: Potential cure for an incurable disease. Expert Opin Biol Ther 2007; 7(12): 1789-1797. (Pubitemid 350247484)
-
(2007)
Expert Opinion on Biological Therapy
, vol.7
, Issue.12
, pp. 1789-1797
-
-
Boyiadzis, M.1
Foon, K.A.2
Pavletic, S.3
-
10
-
-
0033583824
-
Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials
-
CLL Trialists' Collaborative Group
-
CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999; 91(10): 861-868.
-
(1999)
J Natl Cancer Inst
, vol.91
, Issue.10
, pp. 861-868
-
-
-
11
-
-
0344729013
-
Chlorambucil in indolent chronic lymphocytic leukemia. French cooperative group on chronic lymphocytic leukemia
-
Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338(21): 1506-1514.
-
(1998)
N Engl J Med
, vol.338
, Issue.21
, pp. 1506-1514
-
-
Dighiero, G.1
Maloum, K.2
Desablens, B.3
-
12
-
-
84856399637
-
-
German CLL Study Group. Available from (accessed 10 July 2008)
-
German CLL Study Group. Available from: http://dcllsg.web.med.uni- muenchen.de/en/cll7/index.php (accessed 10 July 2008).
-
-
-
-
13
-
-
21144456107
-
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
-
Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23(13): 2971-2979.
-
(2005)
J Clin Oncol
, vol.23
, Issue.13
, pp. 2971-2979
-
-
Moreton, P.1
Kennedy, B.2
Lucas, G.3
-
14
-
-
2942694373
-
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
-
Wendtner CM, Ritgen M, Schweighofer CD et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18(6): 1093-1101.
-
(2004)
Leukemia
, vol.18
, Issue.6
, pp. 1093-1101
-
-
Wendtner, C.M.1
Ritgen, M.2
Schweighofer, C.D.3
-
15
-
-
33744793781
-
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
-
Montillo M, Tedeschi A, Miqueleiz S et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006; 24(15): 2337-2342.
-
(2006)
J Clin Oncol
, vol.24
, Issue.15
, pp. 2337-2342
-
-
Montillo, M.1
Tedeschi, A.2
Miqueleiz, S.3
-
16
-
-
51249108295
-
Therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101
-
Abstract 755
-
Lin TS, Donohue KA, Lucas MS et al. Therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 2007; 110: Abstract 755.
-
(2007)
Blood
, vol.110
-
-
Lin, T.S.1
Donohue, K.A.2
Lucas, M.S.3
-
17
-
-
37549046061
-
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia
-
Del Poeta G, Del Principe MI, Buccisano F et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008; 112(1): 119-128.
-
(2008)
Cancer
, vol.112
, Issue.1
, pp. 119-128
-
-
Del Poeta, G.1
Del Principe, M.I.2
Buccisano, F.3
-
18
-
-
37149029392
-
Methylprednisolonerituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
-
Bowen DA, Call TG, Jenkins GD et al. Methylprednisolonerituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48(12): 2412-2417.
-
(2007)
Leuk Lymphoma
, vol.48
, Issue.12
, pp. 2412-2417
-
-
Bowen, D.A.1
Call, T.G.2
Jenkins, G.D.3
-
19
-
-
40849094878
-
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
-
Dungarwalla M, Evans SO, Riley U et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008; 93(3): 475-476.
-
(2008)
Haematologica
, vol.93
, Issue.3
, pp. 475-476
-
-
Dungarwalla, M.1
Evans, S.O.2
Riley, U.3
-
20
-
-
33746137366
-
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
-
Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20(8): 1441-1445.
-
(2006)
Leukemia
, vol.20
, Issue.8
, pp. 1441-1445
-
-
Pettitt, A.R.1
Matutes, E.2
Oscier, D.3
-
21
-
-
33744824039
-
Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL
-
Abstract 719
-
Wierda WG, O'Brien S, Ferrajoli A et al. Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL. Blood 2005; 106: Abstract 719.
-
(2005)
Blood
, pp. 106
-
-
Wierda, W.G.1
O'brien, S.2
Ferrajoli, A.3
-
22
-
-
45149110164
-
Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL
-
Abstract 628
-
Wierda, WG, O'Brien S, Ferrajoli A et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood 2007; 110: Abstract 628.
-
(2007)
Blood
, vol.110
-
-
Wierda, W.G.1
O'brien, S.2
Ferrajoli, A.3
-
23
-
-
27244451794
-
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial
-
Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23(28): 7024-7031.
-
(2005)
J Clin Oncol
, vol.23
, Issue.28
, pp. 7024-7031
-
-
Elter, T.1
Borchmann, P.2
Schulz, H.3
-
24
-
-
40749128044
-
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication
-
Bosch F, Ferrer A, Villamor N et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008; 14(1): 155-161.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.1
, pp. 155-161
-
-
Bosch, F.1
Ferrer, A.2
Villamor, N.3
-
25
-
-
71049139152
-
NCRI CLL201 Trial: A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL
-
Abstract 324
-
Hillmen P, Pocock C, Cohenz D et al. NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Br J Haematol 2008; 141(Suppl. 1): 119 (Abstract 324).
-
(2008)
Br J Haematol
, vol.141
, Issue.SUPPL. 1
, pp. 119
-
-
Hillmen, P.1
Pocock, C.2
Cohenz, D.3
-
26
-
-
41149097613
-
Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international phase III study
-
Abstract 2043
-
Knauf WU, Lissichkov T, Aldaoud A et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study. Blood 2007; 110: Abstract 2043.
-
(2007)
Blood
, vol.110
-
-
Knauf, W.U.1
Lissichkov, T.2
Aldaoud, A.3
-
27
-
-
4444343395
-
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
-
Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104(6): 1793-1800.
-
(2004)
Blood
, vol.104
, Issue.6
, pp. 1793-1800
-
-
Teeling, J.L.1
French, R.R.2
Cragg, M.S.3
-
28
-
-
38949185742
-
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, inpatients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study
-
Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, inpatients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111(3): 1094-1100.
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1094-1100
-
-
Coiffier, B.1
Lepretre, S.2
Pedersen, L.M.3
-
29
-
-
67649272030
-
Ofatumumab (HuMax-CD20) a novel CD20 monoclonal antibody is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial
-
Abstract 328
-
Osterborg A, Kipps T, Mayer J et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 328.
-
(2008)
Blood (ASH Annual Meeting Abstracts)
, vol.112
-
-
Osterborg, A.1
Kipps, T.2
Mayer, J.3
-
30
-
-
84856366464
-
-
Available at (accessed 10 July 2008)
-
Available at: http://clinicaltrials.gov/ct2/show/NCT00410163 (accessed 10 July 2008).
-
-
-
-
31
-
-
34547691135
-
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
-
Byrd JC, O'Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13(15 Pt 1): 4448-4455.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.15 PART 1
, pp. 4448-4455
-
-
Byrd, J.C.1
O'brien, S.2
Flinn, I.W.3
-
32
-
-
54249121052
-
Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): Results from a phase I/II multicenter study
-
Abstract 7003
-
Byrd JC, Castro JE, Flinn IW et al. Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. J Clin Oncol 2008; 25: Abstract 7003.
-
(2008)
J Clin Oncol
, vol.25
-
-
Byrd, J.C.1
Castro, J.E.2
Flinn, I.W.3
-
33
-
-
84856399638
-
-
Available at (accessed 10 July 2008)
-
Available at: http://clinicaltrials.gov/ct2/show/NCT00391066 (accessed 10 July 2008).
-
-
-
-
34
-
-
27744597929
-
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
-
Chanan-Khan A, Miller KC, Takeshita K et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106(10): 3348-3352.
-
(2005)
Blood
, vol.106
, Issue.10
, pp. 3348-3352
-
-
Chanan-Khan, A.1
Miller, K.C.2
Takeshita, K.3
-
35
-
-
71049120033
-
The assessment of antileucemic activity of thalidomide in combination with fludarabine in patients with newly diagnosed and refractory or relapsed chronic lymphocytic leukemia
-
Abstract 1079
-
Kowal M, Podhorecka M, Gromek T et al. The assessment of antileucemic activity of thalidomide in combination with fludarabine in patients with newly diagnosed and refractory or relapsed chronic lymphocytic leukemia. Haematologica 2008; 93(Suppl1): Abstract 1079.
-
(2008)
Haematologica
, vol.93
, Issue.SUPPL.1
-
-
Kowal, M.1
Podhorecka, M.2
Gromek, T.3
-
36
-
-
33947243663
-
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
-
Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5343-5349
-
-
Chanan-Khan, A.1
Miller, K.C.2
Musial, L.3
-
37
-
-
45949100928
-
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
-
Ferrajoli A, Lee BN, Schlette EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111(11): 5291-5297.
-
(2008)
Blood
, vol.111
, Issue.11
, pp. 5291-5297
-
-
Ferrajoli, A.1
Lee, B.N.2
Schlette, E.J.3
-
38
-
-
45149115902
-
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
-
Andritsos LA, Johnson AJ, Lozanski G et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26(15): 2519-2525.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15
, pp. 2519-2525
-
-
Andritsos, L.A.1
Johnson, A.J.2
Lozanski, G.3
-
39
-
-
20344382459
-
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
-
Flinn IW, Byrd JC, Bartlett N et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005; 29(11): 1253-1257.
-
(2005)
Leuk Res
, vol.29
, Issue.11
, pp. 1253-1257
-
-
Flinn, I.W.1
Byrd, J.C.2
Bartlett, N.3
-
40
-
-
33846219417
-
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
-
Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109(2): 399-404.
-
(2007)
Blood
, vol.109
, Issue.2
, pp. 399-404
-
-
Byrd, J.C.1
Lin, T.S.2
Dalton, J.T.3
|